Office-Based Treatment of Opioid Dependence

Transcription

1 Office-Based Treatment of Opioid Dependence Saturday, November 5, :30 PM to 5:30 PM Mason General Hospital, Shelton, Washington PROGRAM OVERVIEW Washington State is currently facing an epidemic of addiction and deaths related to the use of prescription opioids. This course aims to helps physicians and their clinical teams improve their care of pain and addiction. In 2010, Washington State passed HB 2876, requiring physicians to have 4 hours of education on long acting opioids. This course will satisfy the requirement. The Drug Addiction Treatment Act of 2000 permits physicians who are trained or experienced in opioid addiction treatment to obtain waivers to prescribe certain narcotic drugs in Schedule III, IV or V of the Controlled Substances Act, in their office practices or in a clinic setting, for the treatment of opioid dependence. Both buprenorphine and the combination of buprenorphine with naloxone are approved by the FDA for use in detoxification and maintenance treatment of opioid dependence. This course combines DVD and face-to-face training to meet the requirement for training needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. A DVD will be sent to physicians who register, containing 4 hours of training and an exam. Proof of successful completion of the exam must be printed and brought to the course as part of the process to obtain a waiver for prescribing buprenorphine. The materials will also be posted on Click on Training to access forms and presentations to complete prior to the training. Clinicians should bring the completed forms with them Nov 5 th. WHO SHOULD ATTEND? This program is intended for physicians, medical residents and health sciences medical, pharmacy and nursing faculty. Mid-level providers ARNPs and other non-physician professionals are not eligible for the waiver, but along with other partners in the practice including nurses and counselors or practice managers are strongly encouraged on a space available basis. Attendance is limited to 40. PROGRAM GOALS After attending this session participants will be able to: Describe prerequisites for a physician to begin to prescribe buprenorphine in office-based practice. Discuss clinically relevant pharmacological characteristics of buprenorphine. Identify appropriate patients for office-based treatment of opioid addiction. Describe induction and maintenance protocols. Discuss strategies for integrating psychosocial care with office-based pharmacological treatment. Discuss the management of chronic and acute pain in patients on treatment for opioid dependence. Discuss the Risk Evaluation and Mitigation strategies for buprenorphine use. 1

2 Planning Committee: Roger A. Rosenblatt, MD, MPH, MFR, Professor and Vice Chair, UW Department of Family Medicine RUOP Director - UW School of Medicine, Seattle, WA. Diane Yu, MD, MSPH- Thurston-Mason County Health Officer Cole Mason, MD- President of Thurston-Mason Medical Society Susan Peterson, Executive Director, Thurston-Mason County Medical Society Joseph O. Merrill MD, MPH - Clinical Assistant Professor of Medicine, Attending Physician, Harborview Medical Center, Seattle, WA. Mary Catlin BSN, MPH - Continuing Education Specialist IV, Project Roam, Department of Family Medicine, Seattle, WA. Constance Hirnle MN, RN, BC - Senior Lecturer, Department of Biobehavioral Nursing and Health Systems, UW School of Nursing, Seattle, WA. COMPLETING THE REQUEST FOR A DEA WAIVER Physicians who complete this course will receive the certificate of attendance needed to send to the Secretary of HHS along with the request for the waiver. With your permission, AOAAM/AAAP will report your name directly to the Secretary of HHS within 4 weeks of the program thus eliminating the need for you to send the certificate of attendance. During the course you will have an opportunity to fill out and mail your waiver request. The form will ask you to provide the DEA number of all physicians in the practice who will be prescribing Buprenorphine for opioid addiction and your solo or group practice Tax ID employer identification number. CONTINUING EDUCATION CREDITS CME: This program is approved for 4.0 AOA Category 1-A CME credit hours, pending approval by the AOA CCME. It is also approved for 4.0 AAFP Prescribed Credit hours, which are eligible for the AMA s Physician Recognition Award Credit. CME credits are being provided by SAMSHA funding and are included in the registration fee. Nurses and Nurse Practitioners: contact hours will be available to nurses and other health care professionals.the UW School of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center s Commission on Accreditation. The UW School of Nursing is an approved clock hour provider by the Washington State Board of Education. Provider is approved by the California Board of Registered Nursing, Provider # Psychologists: The UW School of Nursing qualifies as a Washington State CE program sponsor under WA (1). Social Workers, Counselors and Other Disciplines: The UW school of Nursing qualifies as a Washington State CE Program sponsor under WAC (1). For other disciplines, a certificate will be awarded documenting attendance at this offering co-provided by the UW School of Nursing. 2

3 Faculty: Roger A. Rosenblatt MD, MPH, MFR Course Director Professor and Vice Chair, UW Department of Family Medicine RUOP Director - UW School of Medicine Joseph O. Merrill MD, MPH Clinical Assistant Professor of Medicine, Attending Physician, Harborview Medical Center L. Paul Gianutsos MD, MPH Associate Director Swedish Family Medicine Residency Cherry Hill Clinical Associate Professor of Family Medicine University of Washington David J. Tauben MD Clinical Associate Professor, Medicine Medical Director UW Center for Pain Relief, Anesthesia and Pain Medicine Director, Medical Student Education in Pain Medicine Registration: register by ing Mary Catlin that you are interested in attending the course at mccatlin@uw.edu. She will send you a confirmation of admission. CNE will be offered to nurses who attend the entire session, complete the evaluation and the exam, and send in a request to UW CNE for hours. Contact mccatlin@uw.edu for questions. CO-PROVIDER Mason and Thurston County Health Departments, University of Washington School of Nursing, Continuing Nursing Education SPONSORS University of Washington (UW) School of Medicine Thurston-Mason County Medical Society, Mason General Hospital American Osteopathic Academy of Addiction Medicine (AOAAM) Life Sciences Discovery Fund, and the Substance Abuse and Mental Health Services Administration Grant 1H79T The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention 3

4 of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Agenda Buprenorphine in the Office-Based Treatment of Opioid Dependence ( Half and Half Course ) November 5, Mountain View Drive Shelton, WA Roger Rosenblatt MD, MPH, MFr, Course Director 12:30 PM Registration (Sign-in, complete DEA waiver, turn in baseline test, and surveys) 1:00-1:10 PM Welcome and Introduction Rosenblatt 1:10-2:00 PM Opioid Dependence Treatment with Buprenorphine/Naloxone Merrill 2:00-2:45 PM Preventing Addiction through Appropriate Pain Management and Managing Pain in Opioid Addicted Patients Tauben 2:45-3:15 PM Patient Evaluation -- Gianutsos 3:00-3:15 PM Break 3:15-4:30 PM Clinical Use of Buprenorphine in Family Practice and Overview of Clinical Tools Gianutsos 4:30-5:15 PM Case studies -- Rosenblatt 5:15-5:45 PM Exam, Sign Out CME SPONSORS University of Washington (UW) School of Medicine American Osteopathic Academy of Addiction Medicine Life Sciences Discovery Fund, the Robert Woods Johnson Foundation and the Substance Abuse and Mental Health Services Administration Grant 1H79T The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government 4

5 5

6 6